# EDGAR Filing Document

**Accession Number:** 0001521036
**File Stem:** 0001193125-23-074198
**Filing Date:** 2023-3
**Character Count:** 13504
**Document Hash:** ed19e56b8d0ad7194fbc82ad888f2ee1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-074198.hdr.sgml**: 20230320

**ACCESSION NUMBER**: 0001193125-23-074198

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230317

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230320

**DATE AS OF CHANGE**: 20230317

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lantheus Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001521036
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **IRS NUMBER:** 352318913
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36569
- **FILM NUMBER:** 23744738

**BUSINESS ADDRESS:**
- **STREET 1:** 331 TREBLE COVE ROAD
- **CITY:** NORTH BILLERICA
- **STATE:** MA
- **ZIP:** 01862
- **BUSINESS PHONE:** 978 671-8001

**MAIL ADDRESS:**
- **STREET 1:** 331 TREBLE COVE ROAD
- **CITY:** NORTH BILLERICA
- **STATE:** MA
- **ZIP:** 01862

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Lantheus MI Holdings, Inc.
- **DATE OF NAME CHANGE:** 20110517

?xml version="1.0" encoding="utf-8" ? 8-K/A

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K/A

#### (Amendment No. 1)

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): March 17, 2023

------

## LANTHEUS HOLDINGS, INC.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36569** | **35-2318913** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| |
|:---|
| **201 Burlington Road, South Building** |
| **Bedford, Massachusetts 01730** |
| **(Address of principal executive offices) (Zip code)** |

---

#### Registrant's telephone number, including area code: (978) 671-8001

#### Not Applicable

#### (Former name or former address, if changed since last report.)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common stock, par value $0.01 per share | LNTH | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### EXPLANATORY NOTE
This Amendment No. 1 to Current Report on Form 8-K/A (the "Amendment") amends and restates in its entirety the Current Report on Form 8-K (the "Initial 8-K") filed by Lantheus Holdings, Inc. (the "Company") on March 17, 2023 solely to add a new sentence to the end of paragraph one under Item 5.02 below. All other information in the Initial 8-K remains unchanged.

#### Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 4, 2023, the Compensation Committee of the Board of Directors of Lantheus Holdings, Inc. (the "Company") appointed Paul Blanchfield as the President of the Company and its subsidiaries, effective March 20, 2023. With the effectiveness of this appointment, the roles of President and Chief Executive Officer of the Company, currently held by Mary Anne Heino, will be split, and Ms. Heino will continue as the Chief Executive Officer and principal executive officer of the Company.

Mr. Blanchfield, 42, has previously served as the Company's Chief Operating Officer since June 2022, and as Commercial Officer since January 2020. Throughout his career in healthcare he has held a variety of leadership roles in sales, marketing, strategy, and operations. Prior to Lantheus, Mr. Blanchfield worked at Takeda Pharmaceuticals Co. where he served as the Head of the U.S. Immunology Business Unit and managed a multi-billion dollar P&L covering multiple rare diseases products. Prior to his time at Takeda, Mr. Blanchfield served in several different roles at Shire Plc across almost 6 years, including as the Head of U.S. Immunology, General Manager of Nordic-Baltics, Head of Corporate Strategy, and Chief of Staff to the CEO. In his time at Shire, Mr. Blanchfield launched multiple products, worked across nine different countries, oversaw a restructuring to increase commercial focus and reduce costs, and led efforts in mergers and acquisitions, corporate defense, integration, and long-term corporate and portfolio strategy. Prior to his time at Shire, Mr. Blanchfield worked at McKinsey & Company for 5 years, where he focused on health care, marketing, and sales. Mr. Blanchfield earned a Master's of Business Administration and Master of Arts in Education from Stanford University and an AB in Economics from Duke University.

In connection with Mr. Blanchfield's appointment as President, his annual base salary will be increased to $650,000, and his target annual bonus will remain at 60% of his annual base salary. In connection with his new position, Mr. Blanchfield will also be granted equity incentive awards valued at $1,006,390 in the aggregate (based on the closing price of a share of the Company's common stock on April 15, 2023). The equity incentive awards will be comprised of (i) 50% of the aggregate value of the equity incentive award granted in the form of performance stock units with vesting determined based on relative total shareholder return ("rTSR"), which is determined by comparing the performance of the Company's share value (including stock price and the value of distributions made to stockholders) against companies in the S&P 400 Health Care Index over a cumulative three-year performance period measured from January 1, 2023 to December 31, 2025, with a payout range from 0% to 200%, depending on the Company's rTSR performance, (ii) 25% of the aggregate value of the equity incentive award granted in the form of restricted stock units with vesting in three equal annual installments over three years, and (iii) 25% of the aggregate value of the equity incentive award granted in the form of stock options, with the number of underlying shares determined in reference to the Black-Scholes value of the stock options on April 15, 2023, and with vesting in three equal annual installments over three years.

There are no arrangements or understandings between Mr. Blanchfield and any other persons pursuant to which he was appointed as President, there are no family relationships among any of the Company's directors or executive officers, and Mr. Blanchfield has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

A copy of the Company's press release, dated March 17, 2023, announcing, among other things, the appointment of Mr. Blanchfield as President is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

------

#### Item 9.01. Financial Statements and Exhibits
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(d) Exhibits* 

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Exhibit Description** |
| 99.1 | [Press Release of Lantheus Holdings, Inc. dated March 17, 2023, entitled "Lantheus Announces Two Key Executive Promotions".](d405671dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **LANTHEUS HOLDINGS, INC.** | **LANTHEUS HOLDINGS, INC.** |
| By: | /s/ Daniel M. Niedzwiecki |
| Name: | Daniel M. Niedzwiecki |
| Title: | Senior Vice President, General Counsel and Corporate Secretary |

---

Date: March 17, 2023

## Exhibit 99.1

**Exhibit 99.1** 

---

| | | |
|:---|:---|:---|
| ![LOGO](g405671g0317034757676.jpg) | **201 Burlington Road**<br> **Bedford, MA 01730** | **800.362.2668**<br> **www.lantheus.com** |

---

**Lantheus Announces Two Key Executive Promotions** 

*Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer* 

**BEDFORD, Mass.**, March 17, 2023 – Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced that Paul Blanchfield has been promoted to President and Dan Niedzwiecki has been promoted to Chief Administrative Officer.

"Paul was instrumental in the successful launch of the company's PSMA PET imaging agent for prostate cancer and has demonstrated strong leadership, a deep understanding of our industry, and a commitment to excellence that makes him the ideal person to take on the role of President. Since joining the company in 2013, Dan has demonstrated a strong track record of leadership and strategic thinking, which will be invaluable as the company continues to grow and evolve as an organization," commented Mary Anne Heino, Lantheus Chief Executive Officer. "I am confident that Paul and Dan will excel in their new roles, and I look forward to working with them as we continue to drive growth and execute on our purpose to Find, Fight and Follow disease to deliver better patient outcomes."

Mr. Blanchfield joined Lantheus as Chief Commercial Officer in January 2020 and was most recently Chief Operating Officer. As President, he will continue to oversee all aspects of Commercial, Technical Operations & Manufacturing and Quality. In his expanded role, he will also be responsible for the company's Medical function. Prior to Lantheus, Mr. Blanchfield worked at Takeda Pharmaceutical Co. where he served as the Head of the U.S. Immunology Business Unit and managed a multi-billion-dollar P&L covering multiple rare disease products. Prior to Takeda, Mr. Blanchfield worked at Shire Plc for almost six years across several different roles, including as the Head of U.S. Immunology, General Manager of Nordic-Baltics, Head of Corporate Strategy, and Chief of Staff to the CEO. Mr. Blanchfield started his career at McKinsey & Company, where he focused on health care, marketing, and sales. He earned an MBA/MA in Education from Stanford University and an AB in Economics from Duke University.

Mr. Niedzwiecki joined Lantheus in 2013 and has served in positions of increasing responsibility. He brings more than 20 years of broad and diverse legal and business experience in corporate, securities, capital markets, transactional, commercial and compliance matters. In his expanded role, Mr. Niedzwiecki will oversee several critical functions, including Legal and Intellectual Property which he currently oversees and adding Human Resources and Corporate Communications. Mr. Niedzwiecki will continue to serve as the company's General Counsel and Corporate Secretary, as well. Prior to joining Lantheus, Mr. Niedzwiecki was a private equity and mergers and acquisitions attorney with Weil, Gotshal & Manges and, prior to that, a securities and transactional attorney at Palmer & Dodge. Mr. Niedzwiecki started his legal career clerking for the Honorable Frank H. Freedman of the United States District Court for the District of Massachusetts. Mr. Niedzwiecki received a Juris Doctor from Boston University School of Law and a Bachelor of Arts in economics from Williams College.

------

**About Lantheus** 

With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.

**Contacts:** 

Mark Kinarney

Vice President, Investor Relations

978-671-8842

<u>ir@lantheus.com</u> 

Melissa Downs

Senior Director, Corporate Communications

646-975-2533

<u>media@lantheus.com</u>